Sigma-Aldrich — Investor Day (March 2010)
141 slides from Sigma-Aldrich's investor day presentation, Mar 16, 2010
Slide 1: Sigma-Aldrich Corporation: Enabling Science to Improve the Quality of Life
Sigma-Aldrich Corporation Enabling Science to Improve the Quality of Life March 16, 2010 Exhibit 99.1
Slide 2: Cautionary Statement
• Our presentation today will include forward looking statements r elating to the Company ’ s future performance, goals, strategic actions • With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency - adjusted growth, and • Management reports both GAAP and
Slide 3: Jai Nagarkatti, Chairman, President and CEO
Sigma-Aldrich Corporation Jai Nagarkatti Chairman, President and Chief Executive Officer
Slide 4: Agenda
Enabling science to improve the quality of life Agenda Summary Growth Drivers Portfolio Assessment and Financial Roadmap Our Overarching Objective / Plan Overview
Slide 5: Our Overarching Objective
To build on our core capabilities and leverage our financial strength to deliver sustainable above-market growth and create value for our Employees, Customers and Shareholders Our Overarching Objective
Slide 6: Overview
Overview How should you measure success? Plan to achieve our objective Our markets and global trends Who is Sigma-Aldrich?
Slide 7: Delivering Value Through a Diversified Portfolio
Sigma-Aldrich ($ Million) 2009 Revenue $2,148 2009 EBITDA $ 592 2009 Free Cash Flow $ 396 Delivering strong financial performance despite a challenging economy Who is Sigma-Aldrich? Delivering Value Through a Diversified Portfolio
Slide 8: Who is Sigma-Aldrich?
70% Research Consumables 30% Fine Chemicals & Services • Research Business • Manufacturing (SAFC) A Life Science company enabling researchers and manufacturers to improve the quality of life Who is Sigma-Aldrich? • Customers – Academia – Pharma & Biotech – Industrial – Hospitals – Testing Labs • Pro
Slide 9: Markets and Global Trends
Sigma-Aldrich participates in space with significant room for growth Markets and Global Trends Markets
Slide 10: Global Economy Shifting East
Sigma-Aldrich’s plan to capture opportunity: expand presence in emerging markets Markets and Global Trends Global Economy Shifting East *As determined by FTSE Global Equity Index; Source: Global Insight's World Overview Projected GDP Growth GDP in $ Trillions
Slide 11: Shift Towards Biology
Sigma-Aldrich’s plan to capture opportunity: build reputation through innovation in Biology Market and Global Trends Shift Towards Biology Pharmaceutical R&D Increasingly Focused on Biologics
Slide 12: Exponential Importance of the Internet
Sigma-Aldrich’s plan to capture opportunity: Aggressive investment to enhance customer experience Market and Global Trends Exponential Importance of the Internet *World Internet Stats Internet Users Have Increased by Nearly 10 Times in the Past Decade*
Slide 13: Focus on Energy, the Environment and Food Safety
Sigma-Aldrich’s plan to capture opportunity: focused approach in Analytical, Chemistry and Materials Science to support research and manufacturing Market and Global Trends Focus on Energy, the Environment and Food Safety Global Renewable Energy Growth 2008-2018 ($ Billions)
Slide 14: Plan to Achieve Objective
above-market growth and create value for our employees, customers and shareholders To build on our core capabilities and leverage our financial strength to deliver sustainable Plan to Achieve Objective Approach • Site Consolidation Revitalize or divest underperforming assets Redeploy ABC M = Focus o
Slide 15: Initiatives Leverage Competitive Advantage
Initiatives Leverage Competitive Advantage Leverage core competencies through targeted initiatives to create value Plan to Achieve Objective • Share repurchase Capital structure Financial strength • Competitive pricing strategy Pricing Sourcing knowledge • Optimize Supply Chain • Leverage Process Im
Slide 16: Impact of Top Line Growth Initiatives
4% Incremental contribution to top line growth Incremental Impact Initiatives Plan to Achieve Objective Impact of Top Line Growth Initiatives 0.5% Expand Web and B2B capabilities Realign sales effort Optimize Go-to-Market 1.0% Apply our technologies to customers’ unique and evolving supply chains SA
Slide 17: M&A activity will supplement organic growth
M&A activity will supplement organic growth ABC M Targets High Growth Markets Sigma-Aldrich Market Share
Slide 18: Five-Year Financial Targets
Strategic actions build sustainable value Incremental Impact Five-Year Financial Targets How to Measure Success 200-300 bpts Expand cumulative operating margins by 2014 > $2 Billion Free cash flow (five years) 7-8% Top line organic growth (normal economic conditions)
Slide 19: Management Team
Management Team
Slide 20: Portfolio Assessment and Financial Roadmap
Portfolio Assessment and Financial Roadmap Rakesh Sachdev Sr. Vice President, Chief Financial Officer and Chief Administrative Officer
Slide 21: Outline
Outline Capital Structure and Use of Cash Investment Thesis Looking Ahead – Sales Growth Drivers – Profitability Drivers Portfolio Assessment Historical Performance and Trends 2009 Results Recap and 2010 Guidance
Slide 22: 2009 Key Business Highlights
2009 – Key Business Highlights • Strong financial year, despite economic environment – Several records achieved – EPS & Free Cash Flow • Research Biotech growth driven by – Innovative new antibody products – Regenerative medicine – Epigenetic products • Fine Chemicals (SAFC) benefited from sale of c
Slide 23: Full Year 2009 Financial Results
2009 Performance drove EPS and free cash flow to a new record. Free cash flow improvement driven by $70M reduction in inventory Full Year 2009 Financial Results
Slide 24: Pre-tax Margin Improved in 2009
2009 pre-tax margins improved 60 bpts despite currency headwinds and restructuring charges Pre-tax Margin Improved in 2009
Slide 25: 2010 Guidance
Organic Revenue Growth Mid single digits Reported EPS $3.00 to $3.15 Free Cash Flow > $350 million SIGMA-ALDRICH’
Slide 26: Historical Trends: Profitable Sales Growth
Continued a 35 year track record in EPS growth Historical Trends – Profitable Sales Growth • Demonstrated historic performance • Robust business model – even in a downturn
Slide 27: Historical Performance: Shareholder Returns
• Share Price Consistently achieving high ROE. Share price has outperformed the peer and broad market indices Historical Performance – Shareholder Returns
Slide 28: Sigma-Aldrich Portfolio Snapshot
~50% of research business comes from biology products and services Sigma-Aldrich Portfolio Snapshot Mapping Old With New Biology focus in Research Markets *Estimated
Slide 29: Portfolio Snapshot: Another Look
Portfolio Snapshot Another Look
Slide 30: Research Portfolio: Well-positioned for Growth
Financial Impact Addressable Market Characteristics Research Portfolio Significant opportunities in $17 billion addressable market Research Portfolio Well-positioned for Growth (~70% of Total Company) • Lower growth (~5%) • Stable profitable business $7.4B • Broad offering of 18,000 products • Basic
Slide 31: SAFC Portfolio Positioned for Value Creation
Financial Impact Characteristics SAFC Portfolio Significant opportunities in $60+ billion addressable market SAFC Portfolio Positioned for Value Creation (~30% of Total Company) • Asia growth • Benefit from global recovery • Diverse applications – LED lights, LCDs, semiconductors, solar panels Hitec
Slide 32: Sales Growth: Where?
Sales Growth – Where? Above Avera g e Market Growth
Slide 33: Sales Growth: How?
Sales Growth – How? Initiatives to achieve above market g rowth rates
Slide 34: Profitability Drivers
Net 200-300 basis point improvement in operating margin over 5 years Profitability Drivers
Slide 35: Restructuring Activities
Recently Announced Actions Activities Will drive margin expansion Restructuring Activities Selective reduction in workforce Voluntary early retirement program Improve customer service levels Exiting five manufacturing sites in U.S. and Europe Total one-time costs of actions estimated at $31 million,
Slide 36: Capital Structure
Solid liquidity position to fund growth Capital Structure (At December 31, 2009)
Slide 37: Historical Use of Cash (2005 to 2009)
$ Billions Over $1 billion returned to shareholders through share buy-back and dividends Historical Use of Cash (2005 to 2009) Uses $(0.3) Net 0.3 Dividends 0.9 Share buy-back $ 0.6 Acquisitions/Investments $ 1.5 Free cash flow 0.5 Capital expenditures $ 2.0 Operating cash flow Funded with debt
Slide 38: Future Uses of Cash
Expect free cash flow to be in excess of $2 billion over next five years Future Uses of Cash 2010 and Beyond • Fund organic growth through technology, partnerships, licensing and go-to-market investments • Fund inorganic growth • Cash dividends • Share repurchases • Debt reduction
Slide 39: Inorganic Opportunities
Inorganic Opportunities Adds to Overall (Licenses, Partnerships, SIAL Growth JVs, Acquisitions) aie PP . Strategic Filter Financial Filter * Product/Technology Expansion * Exceed Overall Financial Target ~ Analytical - Sales Growth >10% - Biology - ROI ~20% - Materials Science * Product and Distribu
Slide 40: Investment Thesis: Why Sigma-Aldrich Now?
Value Creation Si g ma-Aldrich Advanta g e Investment Thesis Why Sigma-Aldrich Now? • Manufacturing and distribution footprint optimization • Demonstrated ability to achieve earnings and cash flow savings from global supply chain and process improvement initiatives • Margin expansion from profitable
Slide 41: Analytical
Analytical Frank Wicks President, Research Essentials/ Research Specialties
Slide 42: Analytical Chemistry Is
Platform recognized for its innovation and breadth Analytical Chemistry Is: The study of the chemical/biochemical composition of matter It asks and answers three fundamental questions: • What is the material present? • How much is present? • What is the quality?
Slide 43: Typical Analytical Process
Sample Induction Sample Collection Sample Preparation (Separation) Detection Data Collection and Analysis Typical Analytical Process Material to be Analyzed Analyzer System Results
Slide 44: Important Questions Answered by Analytical
Important Questions Answered by Analytical • How do the manufacturers of your multi-vitamin tablets know they contain the right amounts of the right vitamins? How do they know the tablets don’t degrade or spoil? – Analytical Chemistry • How do researchers know if they have synthesized the right chem
Slide 45: How Analytical Fits Within Our Research Growth Strategy
How Analytical Fits Within Our Research Business Growth Strategy ABC M Our customers use analytical technology combined with chemistry, biology and/or materials science in all stages of their workflow from “Discover to Apply”
Slide 46: Analytical Market Overview
Market growth of 5% Analytical Market Overview * Source: SDI, Analyst Reports, Team Analysis * Includes instruments (HPLC, GC, TLC, LPLC, IC, flash chromatography), consumables, standards and reagents Market by Product Type
Slide 47: Global Analytical Market Overview
• Market by customer segment Global Analytical Market * Overview • Environmental – Testing pollutants in water, air and soil • Biotech – Sample prep and analysis of large bio-molecules, bio-markers, etc. • Food & Beverages – Testing nutrients, ingredients, additives and impurities • Pharmaceutical –
Slide 48: Analytical Innovative Solutions
• Hydranal • SPME • dSPE • Ascentis Improving the quality of life Analytical Innovative Solutions For Environmental, Food Safety and Pharmaceutical Testing ® • The “gold standard” for water content testing • Positively impacts environment by reducing chemicals required for analytical testing • Facil
Slide 49: Analytical Growth Strategy
Expanding analytical innovation Analytical Growth Strategy • Become the “Aldrich” of analytical standards and reagents • Chemical analysis – Increased emphasis in food safety and the environment • Additional capability for collaborative innovation with academia and industry – Increased R&D and busin
Slide 50: Going Forward
Going Forward To achieve >10% top-line sales growth, we will become the leading provider of analytical consumables and know-how • Known as “the source” for the highest quality analytical consumables • The commercial partner-of-choice for analytical consumable innovators • A valued, sought-after prob
Slide 51: Chemistry
Chemistry Frank Wicks President, Research Essentials/ Research Specialties
Slide 52: Chemistry Is
Chemistry Is: The science of matter and the changes it undergoes Sigma-Aldrich – “Organic molecules used in scientific research”
Slide 53: Chemistry Market Overview
Market growth 2 - 3% Market Overview • $1B in size • The users are most often the buyers • Main segments are Pharma, Biopharma, Academia, Industrial • Pharma segment hard hit by consolidation of the industry, trend towards big molecules and general cost savings in R&D • Academia and governmental seg
Slide 54: Materials Science is a fast growing market segment
Materials Science is a fast growing market segment Chemistry • Chemical Synthesis – most comprehensive product range of simple molecules to enable creation of more complex molecules • Organic Building Blocks – basic molecules used especially in drug discovery • Stable Isotopes – isotopically labeled
Slide 55: Chemistry Growth Strategy
We will deliver 3 - 4% growth Chemistry Growth Strategy • Aldrich is the premier brand with 40% market share • Broadest selection of 50,000 products – add 1,000 new annually • Sales channels – mainly catalog and e-channels • One-half million catalogs distributed • Aldrichimica Acta – leading organic
Slide 56: Materials Science
Materials Science Frank Wicks President, Research Essentials/ Research Specialties
Slide 57: Materials Science Is
Materials Science Is: A field of study that focuses on specific groups of materials with particular properties of high technological value and their applications towards devices
Slide 58: How Materials Science Fits Within Chemistry Growth Strategy
How Materials Science Fits Within Sigma-Aldrich’s Chemistry Growth Strategy • Chemical knowledge for Life Science applications carries over to high technology • Faster growing applications area – capturing flat panel displays, environmental • Over the past 6 years we have: – Positioned the Aldrich b
Slide 59: Materials Science Market Overview
Development market twice the size of research market Key Drivers Macro Trends • • • Materials Science Market Overview Global Materials Science R&D Market • $0.5 billion • Competition is fragmented • Market growth – 9% – Big and growing in size and diversity – Funding intact – Our target markets are
Slide 60: Materials Science Growth Strategy
Reach non-traditional customers Materials Science Growth Strategy Use innovation focused approach to fill the gaps: • Accelerate new product introduction on existing platforms • Create new offerings for development customers • Enhance analytical capabilities • Polymers • Metals • Ceramics Expand our
Slide 61: Materials Science: Going Forward
• Objective: > 10% growth • Scope: • Key Growth Strategies Deliver > 10% growth Going Forward • To supply high quality materials and services to scientists and engineers engaged in fundamental and applied materials science research worldwide and in the development of innovative products in select ma
Slide 62: Biology
Biology David Smoller President, Research Biotech
Slide 63: Biology Is
• A natural science concerned with the • Challenge Biology Is: study of life and living organisms • Understanding the dynamics of the complex biological pathways and molecular interactions within living cells
Slide 64: Biology Segments
Comprehensive portfolio of life science products – $800 million Biology Segments
Slide 65: How Biology Fits within Research Growth Strategy
How Biology Fits within our Research Business Growth Strategy • Biology is a complimentary technology to chemistry in the life science workflow from “Discovery to Drug” • Life science research moving towards understanding complex biological pathways and entire biological systems • R&D grants awarded
Slide 66: Biochemistry / Biology Market
Business Unit Market Size ($ Millions) Market Growth Biochemistry / Biology Market Biomolecules RB $1,900 9% Functional Genomics RB Cells & Cell Based Assays RB Protein Assays RB Transgenics & Services RB 2,000 Genomics RB 1,800 Cell Culture RE/RS Specialty Biochem and Enzymes RE/RS Lab Essentials R
Slide 67: Sigma is Where Bio Begins
Sigma is “Where Bio Begins” for our Customers
Slide 68: Biology Segments
Comprehensive portfolio of life science products – $800 million Biology Segments
Slide 69: Largest Breadth of Traditional Biochemistry Products
Basic tools for Biochemical research Largest Breadth of Traditional Biochemistry Products • Offer over 18,000 products • Add 500 new products each year to support the latest cutting edge research • Largely sold through the catalog and e-channels – Over one-half million catalogs distributed • Over on
Slide 70: Largest Breadth of Traditional Biochemistry Products
Will deliver 5% growth annually Largest Breadth of Traditional Biochemistry Products • Cell Culture – Complete range of media and components to grow a variety of cell types • Specialty Biochem and Enzymes – Industry leading offering of products for basic Biochemical research • Lab Essentials – Broad
Slide 71: Biology Segments
Comprehensive portfolio of life science products – $800 million Biology Segments
Slide 72: Biologically Rich Content Products
Biologically rich content products Leading Biomolecule Provider Biological Rich Content • Leading biomolecule supplier with 4,000 bioactive small molecules and thousands of proteins and peptides used for life science research • Number one oligo synthesis world-wide with manufacturing in all regions
Slide 73: Functional Genomics and Regenerative Medicine
Leading the Industry Functional Genomics and Regenerative Medicine • Unparalleled gene editing technology – CompoZr™ Zinc Finger Nucleases (ZFN) • Cutting-edge gene silencing products – Mission ® siRNAs and the largest set of validated lentivirus based shRNA clones • Innovative set of reagents for r
Slide 74: New Paradigm in Animal Models
New Paradigm in Animal Models • Most relevant model system for your research – Rat – Mouse – Other • Addresses currently unmet needs – ADME – CNS disease – CV disease – Hypertension – Immunodeficiency models – Increased productivity Sigma Publishes in Science on the First KO Rat
Slide 75: Sigma Acquires Ace Animals, Inc.
Sigma Acquires Ace Animals, Inc. • High quality research rodents to the biomedical industry since 1973 • Brings rodent breeding and distribution capabilities and marries them to our SAGE™ Labs animal creation business
Slide 76: Leveraged ZFNs in Cell-based Assays
ZFNs used to label organelles in a living cell Leveraged ZFNs in Cell-based Assays
Slide 77: Power of ZFNs in Stem Cell Research
Power of ZFNs in Stem Cell Research YFP + Pluripotent Stem Cells
Slide 78: Connecting with Scientists
Connecting with Scientist Information and Social Networking
Slide 79: Biology: Going Forward
Sigma is the only company that is positioned to do this Going Forward • To achieve double-digit top line sales growth – become leader in specific market segments within the cell biology market and differentiated animal models market by: – Acquiring new biologically rich content products – Leverage p
Slide 80: Biology Segments Growth
Overall growth >7% Biology Segments 5% Growth >10% Growth
Slide 81: Go To Market
Go To Market Gerrit van den Dool Vice President, Sales
Slide 82: Customer Profiles
• • • • Different customer types “My reps should bring me new ideas; updated equipment and reagents - that is really helpful.” -Biologist “What I really like about my rep is the ability to call someone when I have problems and know that they will fight to get my problem resolved.” -Enterprise Resear
Slide 83: Coverage Strategies
Varied customers require different approaches Go To Market Coverage Strategies Initiatives
Slide 84: Biologists require higher touch
Biologists require higher touch Go To Market Adjustments • Biologists require higher touch • Realign sales force to achieve more focused coverage • No substantial change in total sales force Level of “Optimal” Rep Interaction 1 Contact preference of at least once every 1-6 months 2 Contact preferenc
Slide 85: Strategic Accounts
Customized approach for global customers Go To Market Strategic Accounts Coordinate efforts across Research and SAFC for Biopharma customers at this level Coordinate efforts across all segments at this level Specialized management level personnel to cover Global accounts
Slide 86: SAFC
SAFC Gilles Cottier President, SAFC
Slide 87: SAFC Is
Unique manufacturing capabilities for Life Science and High Technology commercial applications SAFC Is:
Slide 88: SAFC Capabilities and Supply Solutions
Complex custom development ‘Small molecule API and biologics High potency and viral particles Technical expertise and project management Critical raw materials for cell culture manufacturing Raw materials characterization Custom media development and services Cell line engineering with ZFN technolog
Slide 89: Leverages Our Research Business
Leverages Our Research Business • Leverage research assets • Utilize our scientific knowledge • Leverage same customer base from research to commercial applications
Slide 90: SAFC Market Size and Growth
SAFC Supply Solutions SAFC Pharma SAFC. Biosciences SAFC Hitech ial Raw Materials terials Diagnostic Raw Materials Flavors & Fragrances General API's & Pharma Intermediates Generic API's Biologics API's Biopharma Raw Materials, Chemicals for Silicon & ‘Compound Semiconductors Chemicals for Solar Ene
Slide 91: Unique Manufacturing Capabilities
Enabling science to improve the quality of life Unique Manufacturing Capabilities Application Examples of Our Technologies • Late phase Antibody Drug Conjugates (ADCs) and viral products for various cancer treatments • Adjuvants and critical raw materials for vaccines • High purity compounds for Lig
Slide 92: SAFC Project Pipeline
Pipeline getting stronger SAFC Project Pipeline Pharmaceuticals and Biopharmaceuticals
Slide 93: SAFC Strategy
SAFC Strategy • Pursue selective commercial opportunities utilizing distinctive technologies and competencies which leverage our scientific knowledge and allow us to maximize our return • Get closer to large life science customers with comprehensive capabilities offer • Leverage quality leadership p
Slide 94: SAFC Growth Initiatives and Unique Manufacturing Capabilities
$100 million additional sales within next three years SAFC Growth Initiatives and Unique Manufacturing Capabilities • Cell lines engineering with Zinc Finger Nuclease (ZFN) for commercial therapeutic protein production • High Potency Active Pharmaceutical Ingredient (HPAPI) and viral particles for c
Slide 95: Cell Line Engineering with ZFN Technology: Market Dynamics
Cell line engineering enable significant improvement in productivity and reliability of commercial therapeutic protein production Cell Line Engineering with ZFN Technology Market Dynamics Pharmaceutical Biologics • Has become an established production process in biological pharmaceutical production
Slide 96: Cell Line Engineering with ZFN Technology
• Unique Capabilities and Benefits Acquired exclusive rights for ZFN technology for bioproduction systems in October 2009 Cell Line Engineering with ZFN Technology • ZFN versus traditional cell line engineering approach – Cut cell line development time by 50% (six months versus 12 months) – Ability
Slide 97: Cell Line Engineering with ZFN Technology
Cell Line Engineering with ZFN Technology
Slide 98: HPAPI and Viral Particles for Oncology/Vaccine
Oncology is becoming number one therapeutic area HPAPI and Viral Particles for Oncology/Vaccine Technology Trends • Increasing complexity and potency of drugs • Monoclonal antibodies to reach and react with cancer specific tissue • Blend technologies to achieve targeted and specified results • Vacci
Slide 99: HPAPI and Viral Particles: Technology Investment
• Technology Investment Investment of over $90 million in the last three years, expanding ‘technology solutions’ throughout the drug development lifecycle HPAPI and Viral Particles for Oncology/Vaccine
Slide 100: HPAPI and Viral Particles: Unique Manufacturing Capabilities
• Unique Manufacturing Capabilities Leadership position = Double digit growth for these technologies in 2009 HPAPI and Viral Particles for Oncology/Vaccine • World leader for high potent active pharmaceutical ingredient production • Largest and leading CMO for production of viral vectors • Leading c
Slide 101: Compound Semiconductors for LED: Market Dynamics
Lighting will undergo the same upheaval as the film and music business Compound Semiconductors for LED Market Dynamics Source: Phillips Lighting 2009 Source: ‘LED LCD TV Roadmap and Market Forecast by Maker’ December 2009, Displaybank Global LED LCD TV Market Forecast General Illumination Market
Slide 102: Compound Semiconductors for LED
Well positioned to capture market explosive growth • Unique Capabilities Compound Semiconductors for LED • SAFC Hitech – leader in manufacturing and distributing key metal organics for the LED Market – Trimethyl Gallium, Trimethyl Indium, Triethyl Gallium, Trimetyl Aluminium • Global manufacturing f
Slide 103: SAFC: Going Forward
• Our Key Growth Initiatives SAFC objective > 7% growth Going Forward • Well positioned to respond to fast growing end-markets • Balanced portfolio between innovative technologies and traditional capabilities • Aligned to mega-trends – Shift from chemistry towards biology – Increasing complexity and
Slide 104: Geographic Expansion
Geographic Expansion Eric Green Vice President and Managing Director, International
Slide 105: Emerging markets have significant growth potential
Emerging markets have significant growth potential Market Drivers and Trends • Emerging markets will represent 43% of global GDP by 2018 • Developing countries aggressively boosting R&D funding • Pharmaceutical companies increasingly rely on off-shoring and out-sourcing • Local companies are emergin
Slide 106: International Markets (Asia Pacific and Latin America)
• • Direct presence in 14 International countries International Markets (Asia Pacific and Latin America) Mexico Brazil Argentina Chile 10% 90% South Korea Japan China Taiwan Vietnam Malaysia India Singapore Australia New Zealand
Slide 107: Strong Performance In International Markets
Emerging regions playing larger role Strong Performance In International Markets
Slide 108: Current International Profile
Current International Profile
Slide 109: Key Growth Drivers
Key Growth Drivers
Slide 110: Go-To-Market
Country specific modes of customer interaction remain essential • Expand sales force coverage • Optimize pricing strategy • Drive e - adoption Go-To-Market • Invest in technical selling to support ABC M strategy • Extend reach into new geographies • Invest in web localization • “Ease of Use” is our
Slide 111: Infrastructure Expansion
Infrastructure remains a key differentiator as we drive demand • • • Infrastructure Expansion Expand distribution capabilities • Existing geographies • New geographies Continue to differentiate through service • Optimize inventory management Adapt our logistics capabilities to support new product li
Slide 112: Localization of Supply
Increase share and margins through local sourcing Localization of Supply • Qualify and develop in-country sources for selected product categories • Invest in local QC and packaging infrastructure • Leverage in-country sources through global supply chain integration * Sigma-Aldrich Estimate Laborator
Slide 113: Acquisitions and Partnerships
Bolt-on acquisitions targeted to support ABC growth in international M Acquisitions and Partnerships • Increase emphasis on targeting inorganic growth opportunities in the region • Form strategic partnerships with local and global companies • Identify technologies and capabilities to support ABC M s
Slide 114: Conclusion and Summary
To achieve 30% of corporate sales by 2014 Conclusion and Summary • We have a sustainable growth strategy • The growth trend for emerging markets remains strong • We are investing in strategic capabilities while focusing on selling and supply chain • We will seek to supplement our organic growth with
Slide 115: eBusiness
eBusiness Amanda Halford Vice President, eBusiness
Slide 116: Our Vision
“I firmly believe that companies that win the battle of e-commerce will win the war in our competitive environment.” Jai Nagarkatti, October 2009 Our Vision Transition from a “catalog” company with a website to a “web” enabled company with a catalog • Drive our ABC M strategy through Internet leader
Slide 117: Fastest Growing Channel to Market
• Key eBusiness is a key driver for overall growth Fastest Growing Channel to Market Will Accelerate Growth Statistics – • 45% of global research sales vs. 4% in 2000 • 54% of U.S. research sales vs. 7% in 2000 • 3 million monthly visits vs. 600k in 2000 $700 M through the web in 2009
Slide 118: Opportunities at Each Stage of Online Buying Cycle
Opportunities to Drive Revenue at Each Stage of the Online Customer Buying Cycle Learn Choose Use
Slide 119: Largest Channel to Market
Largest Channel to Market Driving Strategy As our single largest channel to market, our website will drive our ABC M strategy Segmentation
Slide 120: Customer Insight
Customer Insight Creating a Differentiated Customer Experience • Observes customers in their work environment • Watches how they actually work, not just listening to what they say they do • Translates observations into functionality that enhances customer’s experience Localization Personalization
Slide 121: New Technologies
New Technologies Accelerated Access to Our Unrivalled Scientific Knowledge
Slide 122: Did You Know?
• Number of internet devices by year Did You Know? • 1984 – 1,000 • 1992 – 1,000,000 • 2008 – 1,000,000,000
Slide 123: Growing Online Market
Growing Online Market Accelerating Revenue Growth As a Web-enabled company, we will take full advantage of the growing online market to accelerate revenue growth
Slide 124: Global Supply Chain
Global Supply Chain Dave Julien President, Global Supply Chain
Slide 125: Sigma-Aldrich Global Supply Chain 2010 and Beyond
An integrated effort Sigma-Aldrich Global Supply Chain 2010 and Beyond Manufacturing Distribution/Logistics Quality Control Centers of Excellence Product Portfolio Management Packaging Procurement Planning
Slide 126: Global Supply Chain Project Goals
• Global Integration • People • Processes Faster, better and more cost-effective Global Supply Chain Project Goals – • Organization • Supply Chain governance • Metrics • Systems (SAP) • New capabilities and expertise • Complexity reduction • Flexibility • Risk reduction
Slide 127: Global Supply Chain Progress
• Procurement and planning • Manufacturing, QC and packaging • Product portfolio • Logistics and distribution • Systems and harmonization Teams formed and projects active Global Supply Chain Progress – • Global organization • Harmonizing, global teams • Eliminating overlaps • Global management • Pro
Slide 128: Global Supply Chain 2009 Results
• 2009 Results Pulled projects forward in 2009, beat targets Global Supply Chain • Inventory Reduction From 7.0 to 6.5 MOH ($75M) • Supply Chain Savings Net $22 Million • Process Improvement Savings $15 Million • Procurement 75% of Total Savings • Service > 90% Available Globally
Slide 129: Global Supply Chain 2010 Targets
• 2010 Targets 2010 targets similar to 2009 Global Supply Chain • Inventory Reduction < 6.5 MOH • Supply Chain Savings Net $15 Million • Process Improvement Savings $15 Million • Service Rates Maintained or improved from 2009 • Systems SAP installations to be completed at major sites
Slide 130: Procurement 2010 Goals
Procurement still largest opportunity Global Supply Chain Procurement – 2010 Goals • Total spend greater than $1 Billion – 50% direct / 50% indirect • Almost a decade into initiative; increased focus 2007 – $110 Million plus saved • Sigma-Aldrich procurement controls 55%, target 80% • Continued focu
Slide 131: Procurement savings hitting peak
Procurement savings hitting peak Global Supply Chain Procurement 2010 Supply Chain Project
Slide 132: Planning 2010 Goals
Decreased inventory by $100+ million while improving fill rates Global Supply Chain Planning – 2010 Goals • Priority planning for new products • Special focus on fastest selling products • Implementing advanced planning system tools • Continued emphasis on reducing inventory write-offs • Reducing cy
Slide 133: Manufacturing, QC and Packaging
Global strategy developing Global Supply Chain Manufacturing, QC and Packaging – • Active global teams developing 5-year strategies • Facilities optimization – centers of excellence – capacity utilization – regional requirements • Packaging component consolidation ($60M spend) • Process, testing and
Slide 134: Distribution Initiative: Customer Focus
Customized solutions to drive sales Global Supply Chain Distribution Initiative – Customer Focus – • High stock availability – 96% for U.S. and Europe – 80% for China and India • 24-hour service to the key markets • Highly automated distributon center in Europe • Excellence in handling chemicals • G
Slide 135: Distribution Initiative: Capacity
8 million units in stock to support our customers Global Supply Chain Distribution Initiative – Capacity SD Mke StL
Slide 136: Distribution Initiative: Significant contribution to savings
Significant contribution to savings Global Supply Chain Distribution Initiative – • Global harmonized processes to improve efficiency • Inventory optimization through global management • Continuous improvement to global network • Development of customized solutions • Optimize regional centers • Expa
Slide 137: Supply Chain Pre-tax Savings
Ahead of plan, potential to beat targets Global Supply Chain Pre-tax Savings 2% pretax margin improvement by 2014 Supply Chain Expected Savings
Slide 138: Summary
Summary Jai Nagarkatti Chairman, President and Chief Executive Officer
Slide 139: Compelling investment opportunity
Compelling investment opportunity Sigma-Aldrich Uniquely Positioned for Value Creation History of profitable growth Strong financial position and cash flow Plans to enhance growth rates and improve profitability Diversified portfolio: products, customers, geography Unrivaled scientific knowledge and
Slide 140: Summary: Why Sigma-Aldrich Now?
Value Creation Sigma-Aldrich Advantage Summary Why Sigma-Aldrich Now? • Manufacturing and distribution footprint optimization • Demonstrated ability to achieve earnings and cash flow savings from global supply chain and process improvement initiatives • Margin expansion from profitable sales growth
Slide 141: Questions?
Questions? Call the conference telephone number Toll free: 877-660-8922 Access code: 4999095 Sigma-Aldrich Corporation